Immunohistochemical expression of TGF-β1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: A clinicopathologic study

International Journal of Gastrointestinal Cancer

Volumn 32, Issue 2-3, 2002, Pages 83-89

  Zolota, Vassiliki ^a,b   Batistatou, Anna ^a   Tsamandas, Athanassios C ^a   Iliopoulos, George ^a   Scopa, Chrisoula D ^a   Bonikos, Dionysis S ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b NONE   (Greece)

Author keywords

Angiogenesis; Gastric carcinoma; Ki67; p21WAF1; p53; TGF 1

Indexed keywords

KI 67 ANTIGEN; POLYPEPTIDE; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROVASCULATURE; PATHOLOGY; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA;

EID: 0038308403     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:32:2-3:83     Document Type: Article

References (25)

1. Roberts AB, Sporn MB. The transforming growth factor-βs, in Peptide Growth Factors and Their Receptors, Sporn MB, Roberts AB, eds. Springer Verlag: Heidelberg, 1990, pp. 419-472.
2. Dickson RB, Lippman ME. Molecular determinants of growth, angiogenesis, and metastasis in breast cancer. Semin Oncol 1992;19:286-298.
3. Gorsch SM, Memoli VA, Stukel TA, et al. Immunohistochemical staining for transforming growth factor-β1 associates with disease progression in human breast cancer. Cancer Res 1992;51:6949-6952.
4. Naef M, Ishiwata T, Friess H, et al. Differential localization of transforming growth factor-β isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int J Cancer 1997;71:131-137.
5. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor β in fibroblastic and epithelial cells. J Biol Chem 1994;269:6271-6274.
6. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-β-induced inhibition of T cell function: susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146:1077-1082.
7. Laiho M, Keski-Oja J. Growth factor in the regulation of pericellular proteolysis: a review. Cancer Res 1989; 49:2533-2553.
8. Yanagihara K, Tsumuraya M. Transforming growth factor β1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 1992;52: 4042-4045.
9. Yoo YD, Choi JY, Lee SJ,et al. TGF-beta-induced cell-cycle arrest through the p21 (WAF1/CIP1)-G1 cyclin/ Cdks-p130 pathway in gastric-carcinoma cells. Int J Cancer 1999;83:512-517.
10. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
11. Yokozaki H, Kuniyasu H, Kitadai Y, et al. p53 point mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol 1992;119:67-70.
12. WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996; 180:122-128.
13. Saito H, Tsujitani S, Oka S, et al. The expression of transforming growth factor-β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999;86:1455-1462.
14. Lauren P. The two histologic main types of gastric carcinoma. Diffuse and so-called intestinal typed carcinoma. Acta Pathol Microbiol Scand 1965;64:31-45.
15. Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5: 4079-4084.
16. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992; 119:1017-1021.
17. Jasani B, Wyllie FS, Wright PA, et al. Immunocytochemically detectable TGF beta is associated with malignancy in thyroid epithelial neoplasia. Growth Factors 1990; 2:149-155.
18. Friess H, Yamanaka Y, Buchler MW, et al. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-1856.
19. Hirayama D, Fujimori T, Satonaka K, et al. Immunohistochemical study of epidermal growth factor and transforming growth factor-β in the penetrating type of early gastric cancer. Hum Pathol 1992;23:681-685.
20. Akagi M, Yasui W, Akama Y, et al. Inhibition of cell growth by transforming growth factorβ1 is associated with p53-independent induction of p21 in gastric carcinoma cells. Jpn J Cancer Res 1996;87:377-384.
21. Kaye PV, Radebold K, Isaacs S, et al. Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of interrelationship or correlation with prognosis. Eur J Surg Oncol 2000;26:39-43.
22. Liu XP, Tsushimi K, Tsushimi M, et al. Expression of p21 (WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation and prognosis. Cancer Lett 2001;170:183-189.
23. Ikegushi M, Saito H, Katano K, et al. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 1998; 43:964-970.
24. Erenoglu C, Akin ML, Uluutku H, et al. Angiogenesis predicts poor prognosis in gastric carcinoma. Dig Surg 2000; 17:581-586.
25. Maehara Y, Kabashima A, Koga T, et al. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 2000;128:408-416.